{{Drugbox
| IUPAC_name = 5-[(2-Benzyl-3,4-dihydro-2''H''-chromen-6-yl)methyl]-1,3-thiazolidine-2,4-dione
| image = Englitazone.svg
| width = 222

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 109229-58-5
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 60303
| ChemSpiderID = 54375
| ChEMBL = 17669
| UNII = ZQW5577C3O

<!--Chemical data-->
| C=20 | H=19 | N=1 | O=3 | S=1 
| molecular_weight = 353.43 g/mol
| smiles = O=C1NC(=O)SC1Cc4ccc3OC(Cc2ccccc2)CCc3c4
}}

'''Englitazone''' is a [[hypoglycemic]] agent of [[thiazolidinedione]] (''glitazone'') class.

== See also ==
* [[Ciglitazone]]
* [[Darglitazone]]
* [[Netoglitazone]]
* [[Troglitazone]]
* [[Rivoglitazone]]—currently in clinical trials
* [[Pioglitazone]], [[lobeglitazone]], [[rosiglitazone]]—the only ones currently in clinical use

== References ==
{{Reflist|2}}

{{Oral hypoglycemics}}
{{PPAR modulators}}

[[Category:Chromanes]]
[[Category:Thiazolidinediones]]